Alper SEYHAN, Baki ERDEM, Emel CANAZ, Hakan GÜRASLAN, Ayşegül BESTEL, Özgür AKBAYIR

Persistan Gestasyonel Trofoblastik Neoplazide Metotreksat Kullanımına Bağlı Nadir Görülen Kutanöz Ülserler: Olgu Sunumu

Giriş: Metotreksat; değişen rejim ve dozlarda çeşitli endikasyonlarda günümüzde yaygın kullanım alanı bulan, folik asit metabolizmasını antagonize eden kemoterapotik ajandır. Kullanım alanları, başta romatolojik hastalıklar olmak üzere, hematolojik maligniteler, gestasyonel trofoblastik neoplaziler ve bazı solid tümörleri içerir. Kullanım sırasında doz bağımlı ya da dozdan bağımsız olarak çeşitli toksik etkileri görülebilmektedir. Toksisiteyi önlemek için çeşitli medikasyonlar kullanılmaktadır. Ancak tüm koruyucu yaklaşımlara rağmen kişisel ve genetik farklılıklar tedavi sonuçlarını etkilemektedir

Rare Cutaneous Ulcers Related to Methotrexate Use in Persistant Gestational Trophoblastic Neoplasia: A Case Report

Introduction: Methotrexate is a chemotherapeutic agent which inhibits the folate metabolism is a frequently used in different disease spectrum; malignancies (hematologic malignancies, solid tumors, gestational neoplastic diseases...) or non-malignant such as chronic inflammatory diseases or dermatologic diseases. While it's using, different toxic side effects can be seen which are dose-dependent or not. Different types of medications are used to prevent toxic side effects. Despite all preventive approaches, personal and genetic differences effect treatment results

PDF

___

Mc Kendry RJ. The remarkable spectrum of methotrexate toxi- cities. Rheum Dis Clin North Am 1997;4:939-54.
Van Ede AE, Laan RF, Blom HJ, De Abreu RA. van de Put- te LB. Methotrexate in rheumatoid arthritis: an update with fo- cus on mechanisms involved in toxicity. Semin Arthritis Rheum 1998;5:277-92.
Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH. Antiinf- lammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 2001;8:729-35.
Athanasios Kalantzis, DDS, MFDS, Zoe Marshman, BDS, MPH, MFDS, DDPH, Denis T. Falconer, BChD, FDSRCS, MB ChB, FRCS, Peter R. Morgan, BDS, BSc, PhD,FRCPath, FDS,and Edward W. Odell, BDS, FDSRCS, MSc, PhD, FRCPath, London, Sheffield, and Romford, UK. Oral effects of low-dose methotrexate treatment: Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;100:52-62
Ince A, Yazici Y, Hamuryudan V, Yazici H. The frequency and clinical characteristics of methotrexate (MTX) oral toxicity in reumatoid arthritis (RA): A masked and controlled study. Clin Rheumatol 1996;15: 491-494.
Khan F, Everard J, Ahmed S, Coleman RE, Aitken M, Hancock BW. Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effect- s:Br J Cancer 2003;15;89(12): 2197-201
Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini, F et al. A randomized trial of parenteral methot- rexate comparing an intermediate dose with a higher döşe in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004 Jul;50(7):2191-201.
Alarcon GS. Methotrexate: its use for the treatment of rheu- matoid arthritis and other rheumatic disorders. In: Koopman W, editor.rthritis & allied conditions. A textbook of rheumatology. 13th ed. London: Williams and Wilkins; 1997.p. 679-98.
Ortiz Z, Shea B, Suarez Almazor M, Moher D,Wells G, Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Data- base Syst Rev 2000;2:CD000951.
Gilani MM, Yarandi F, Eftekhar Z, et al. Comparison of pulse methotrexate and pulse dactinomycin in the treatment of low-risk gestational trophoblastic neoplasia. Aust N Z J Obstet Gynaecol 2005;45:161-4.